Product Name: Rivaroxaban CAS NO:366789-02-8
Chemical & Physical Properties:
Appearance : White to Off-White powder
Boiling Point:732.6℃ at 760 mmHg
Solubility:Soluble in DMSO.
Rivaroxaban was successfully developed jointly by Bayer Pharmaceuticals and Johnson & Johnson. In October 2008, it was approved for listing in Canada and the European Union under the trade name Xarelto. Rivaroxaban is the world's first oral direct factor Xa inhibitor, which can highly selectively and competitively inhibit free and bound factor Xa and prothrombin activity, prolonging the activated partial thromboplastin time plate in a dose-dependent manner (PT) and prothrombin time (aPTT) to extend the clotting time and reduce the formation of thrombin. It has the characteristics of high bioavailability, broad spectrum of treatment diseases, stable dose-effect relationship, convenient oral administration, and low bleeding risk.
Rivaroxaban is also a drug to prevent and treat venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.